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Early Response to Bortezomib Combined Chemotherapy Can 
Help Predict Survival in Patients with Multiple Myeloma Who Are 
Ineligible for Stem Cell Transplantation
Novel agents to treat multiple myeloma (MM) have increased complete respone (CR) 
rates compared with conventional chemotherapy, and the quality of the response to 
treatment has been correlated with survival. The purpose of our study was to show 
how of early response to bortezomib combined chemotherapy influences survival in 
patients with newly diagnosed MM who are ineligible for stem cell transplantation. We 
assessed patient responses to at least four cycles of bortezomib using the International 
Myeloma Working Group response criteria. The endpoints were comparisons of 
progression free survival (PFS) and overall survival (OS) between early good response 
group (A group) and poor response group (B group). We retrospectively analyzed data 
from 129 patients registered by the Korean Multiple Myeloma Working Party, a 
nationwide registration of MM patients. The 3 yr PFS for the A and B groups was 
55.6% and 18.4%, respectively (P < 0.001). The 3 yr OS for the A and B groups was 
65.3% and 52.9%, respectively (P = 0.078). The early response to at least four cycle of 
bortezomib before next chemotherapy may help predict PFS in patients with MM who 
are ineligible stem cell transplantation.
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INTRODUCTION
Multiple myeloma (MM) patients treated with conventional che-
motherapies, such as melphalan and prednisone (MP) or vin-
cristine, doxorubicin, and dexamethasone (VAD), do not com-
monly have a complete response (CR) (1-4). Novel agents for 
treating MM, such as thalidomide, bortezomib, and lenalido-
mide, generally result in an improved response and longer sur-
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vival. Patients undergoing high dose chemotherapy (HDT) plus 
autologous stem cell transplantation (ASCT) and regimens in-
corporating bortezomib, thalidomide, and lenalidomide have 
better responses than patients undergoing conventional che-
motherapy (5-8). Moreover, the quality of a response to a MM 
treatment has been correlated with survival. A CR to induction 
therapy was reported to be a predictive factor of outcome for 
patients undergoing autologous stem cell transplantation (9, 10). 
Moreover, a CR or very good partial response (VGPR) was also 
associated with longer survival in patients not undergoing HDT 
or ASCT (11-14). Especially in elderly patients, an early response 
to therapy was associated with survival in patients with MM (15-
17). Patients with a ≥ 50% decrease in monoclonal protein after 
1 cycle of vincristine, doxorubicin and dexamethasone had a 
better event free survival (EFS) than patients with a < 50% re-
duction (15). Another report showed a survival advantage for 
patients with a decrease in M-protein of 30% or more after 1 MP 
cycle (17). In elderly patients, a treatment can increase the CR 
rate without improving PFS because of a higher toxic death rate, 
poor performance status, and poor compliance with intensive 
therapy or aggressive treatment (18, 19). Bortezomib combined 
chemotherapy, however, is effective and tolerable in elderly pa-
tients with MM (20). 
 Additionally, a relationship between a rapid response and 
outcomes has been demonstrated in patients with relapsed and/ 
or refractory MM who were treated with bortezomib and pe-
gylated liposomal doxorubincin (21). Patients with a rapid re-
sponse had a higher survival rate. To date, there is no data on 
the relationship between an early response and survival in pa-
tients treated with novel agents, including bortezomib combined 
chemotherapy as first-line therapy. The purpose of this study is 
to show the relationship between an early response and surviv-
al in MM patients treated with bortezomib combined chemo-
therapy.
MATERIALS AND METHODS
Patients 
Patients who were newly diagnosed with MM and underwent 
bortezomib combined chemotherapy as first-line therapy be-
tween September 2003 and July 2011 were analyzed retrospec-
tively in this study. Data were collected through the Korean Mul-
tiple Myeloma Working Party (KMMWP), a nationwide registry 
of MM patients. The total number of patients who were treated 
with bortezomib was 1,176 in Korea. However, bortezomib was 
given to only 204 patients as first-line treatment, among which 
75 received autologous stem cell transplantation (ASCT) and 
129 did not receive ASCT. The reason of small number of patients 
treated with first-line bortezomib compared with the total num-
ber is that bortezomib was approved only for those who had 
failed from first-line chemotherapy by the Health Insurance 
Review Agency in Korea.  
 We included patients who were ineligible for hematopoietic 
stem cell transplantion (HSCT) because of their age (65 yr or 
older) or comorbidities. All enrolled patients were treated with 
at least four cycles of bortezomib combined chemotherapy. Pa-
tients who received HSCT or had other malignancies were ex-
cluded. 
Treatment 
In this study, there were 4 different regimens of bortezomib com-
bined chemotherapy. Fifty-seven patients (44.2%) were treated 
with bortezomib plus dexamethasone (VD), comprising an in-
travenous bolus of bortezomib (1.3 mg/m2) on days 1, 4, 8, and 
11, an oral or intravenous bolus of dexamethasone (20 mg fixed 
dose) on days 1-2, 4-5, 8-9, and 11-12, every 3 weeks. Thirty-two 
patients (24.8%) were treated with bortezomib, thalidomide, 
and dexamethasone (VTD), comprising an intravenous bolus 
of bortezomib (1.3 mg/m2) on days 1, 4, 8, and 11, oral thalido-
mide (100 mg) daily, and an oral or intravenous bolus of dexa-
methasone (40 mg) on days 1 to 4, every 3 weeks. Eighteen pa-
tients (14.0%) were treated with doxorubicin, bortezomib, and 
dexamethasone (PAD), comprising an intravenous bolus of bort-
ezomib (1.3 mg/m2) on days 1, 4, 8, and 11, an intravenous bo-
lus of doxorubicin (9 mg/m2) on days 1 to 4, an oral or intrave-
nous bolus of dexamethasone (40 mg fixed dose) on days 1 to 4, 
every 3 weeks. Twenty-two patients (17.1%) were treated with 
bortezomib, melphalan, and prednisone (VMP), comprising an 
intravenous bolus of bortezomib (1.3 mg/m2) on days 1, 4, 8, 11, 
22, 25, 29, and 32, cycles 1 to 4, and days 1, 8, 22, and 29, cycles 5 
to 9, oral melphalan (9 mg/m2) on days 1 to 4, cycles 1 to 9, and 
oral prednisone (60 mg/m2) on days 1 to 4, cycles 1 to 9, every 6 
weeks.  
Response assessment 
International Myeloma Working Group response criteria (22) 
was used to assess responses in all patients receiving bortezo-
mib combined chemotherapy. To determine the early response, 
patients were assessed before cycle 4 or 4 months after starting 
chemotherapy.
 A stringent complete response (sCR) was defined as a nor-
mal free light chain (FLC) ratio and an absence of clonal cells in 
bone marrow by immunohistocheminstry or immunofluores-
cence. CR was defined as negative immunofixation on the se-
rum and urine, disappearance of any soft tissue plasmacytoma, 
and less than 5% plasma cells in bone marrow. A very good par-
tial response (VGPR) was defined as, 1) serum and urine M-pro-
tein detectable by immunofixation but not electrophoresis, or 
90% or greater reduction in serum M-protein, plus 2) urine M-
protein level less than 100 mg per 24 hr. Partial response (PR) 
was defined as a 50% or greater reduction in serum M-protein 
and reduction in 24 hr urinary M-protein of 90% or more or to 
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less than 200 mg. Progressive disease (PD) was defined as a rel-
ative increase of 25% or greater or an absolute increase of 0.5 g/
dL or more in serum or urine M-component or 200 mg or more 
per 24 hr in urine. Stable disease (SD) was defined as not meet-
ing criteria for CR, VGPR, PR or PD.
Statistical analysis
For comparison patients were grouped as VGPR and CR or PR, 
SD, and PD. All patients were divided into these two groups 
based on incidence rates of their early response before cycle 4 
or 4 months after starting chemotherapy. The incidence rates of 
patients with a VGPR or better, and a PR or worse were 51.2% 
and 48.8%, respectively. To compare categorical variables be-
tween the two groups chi-square test was done. OS was defined 
as the time from initiating the study therapy to date of death 
from any cause. PFS was defined as the time from initiating the 
study therapy to date of progressive disease (PD). Patients who 
died without documented PD were considered to have had PD 
at the time of death. Patients lost to follow-up were censored at 
the last contact date. Survival curves were estimated using the 
Kaplan–Meier method.
Ethics statement
The study was approved by the institutional review board the 
Kosin University Gospel Hospital of Korea (IRB No. 2011-93). 
As this was a retrospective study using medical records, informed 
consent was exempted by the board.
RESULTS
Patients 
The median patient age was 63 yr (range from 45 to 76). The male 
to female ratio was 1.08:1.00. The median follow up duration 
from the diagnosis to last follow up date was 20.73 months (range 
from 4.33 to 80.23 months). The median duration from the first 
chemotherapy to evaluation of early response was 2.3 months 
(range from 0.9 to 3.7 months). Other patient characteristics are 
shown in Table 1. 
 All patients were divided into two groups according to their 
early response. Patients with a VGPR or CR composed the A 
group, and patients with a PR, SD, or PD composed the B group. 
All baseline and treatment related factors were similar between 
the two groups, except treatment regimen and additional che-
motherapy after first line chemotherapy. Of the A group, 34.8% 
were treated with VD and 36.4% were treated with VTD; 54.0% 
of the B group was treated with VD. Additional chemotherapies 
were given more frequently in group B than those in group A, 
as shown in Table 2. 
Response and survival rates outcomes 
The response results after chemotherapy are shown in Table 3. 
The early response was CR for 16 patients (12.4%), VGPR for 50 
(38.8%), PR for 40 (31.0%), SD for 14 (10.9%) and PD for 9 (7.0%). 
The best response was CR for 46 patients (35.7%), VGPR for 31 
(24.0%), PR for 32 (24.8%), SD for 11 (8.5%) and PD for 9 (7.0%). 
Table 1. Characteristics of 129 patients 
Parameters No
Age (yr)
   Median (range)
63 (45-76)
Sex (%)
   Male
   Female
 
67 (51.9)
62 (48.1)
Serum M-protein (%)
   IgG, κ type
   IgG, λ type
   IgA, κ type
   IgA, λ type
   Free κ type
   Free λ type
 
50 (38.8)
31 (24.0)
14 (10.9)
14 (10.9)
10 (7.8)
10 (7.8)
ISS (%)
   I
   II
   III
 
29 (22.5)
52 (40.3)
48 (37.2)
Cytogenetics (%)
   Unknown
   Normal
   Abnormal
 
54 (41.9)
23 (17.8)
52 (40.3)
Beta-2 microglobulin, mg/L (%)
   Unknown
  < 2.5
   2.5-5.5
  > 5.5
 
2 (1.6)
16 (12.4)
65 (50.4)
46 (35.7)
Albumin, g/L (%)
  < 3.5
  ≥ 3.5
 
66 (51.2)
63 (48.8)
Calcium, mg/dL (%)
   Unknown
  > 10
  ≤ 10
 
1 (0.8)
17 (13.2)
111 (86.0)
LDH (%)
   Unknown
  < 450
  ≥ 450
 
7 (5.4)
99 (76.7)
23 (17.8)
Creatinine (%)
  < 1.5
  ≥ 1.5
 
94 (72.9)
35 (27.1)
CRP (%)
   Unknown
  < 1.0
  ≥ 1.0
 
17 (13.2)
70 (54.3)
42 (32.6)
Bone lesion, number (%)
   Unknown
   None
   1-3
  > 3
 
2 (1.6)
29 (22.5)
39 (30.2)
59 (45.7)
First line regimen (%)
   VD
   VTD
   PAD
   VMP
 
57 (44.2)
32 (24.8)
18 (14.0)
22 (17.1)
ISS, International staging system; LDH, lactate dehydrogenase; CRP, C-reactive pro-
tein; VD, velcade plus dexamethasone; VTD, velcade, thalidomide plus dexametha-
sone; PAD, doxorubicin, velcade plus dexamethasone; VMP, velcade, melphalan plus 
prednisone.
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 Table 4 shows a comparison of PFS and OS between the A 
and B groups. The 3 yr PFS were higher in the A group than the 
B group (55.6% vs 18.4%, P < 0.001). The 3 yr OS tended to be 
higher in the A group than the B group, though the difference was 
not statistically significant (65.3% vs 52.9%, P = 0.078), (Fig. 1).
 PFS and OS were compared between early responders and 
delayed responders. The early responders (n = 66) included pa-
tients who had a VGPR or CR at an early time point. The delayed 
responders (n = 11) included patients who have a VGPR or CR 
after the fourth cycle or four months of chemotherapy. The 3 yr 
PFS was higher among early responders than delayed respond-
ers (55.6% vs 33.3%, P = 0.031). The 3 yr OS did not differ between 
the groups (65.3% vs 75.0%, P = 0.831) (Fig. 2). 
 We next analyzed the effect of each chemotherapy regimens 
on PFS and OS. The 3 yr PFS was significantly higher for the A 
group when treated with VD, VTD, or PAD (VD; P = 0.002, VTD; 
P = 0.001, PAD; P = 0.002, and VMP; P = 0.119). The 3 yr OS was 
only significantly higher for the A group treated with PAD (VD; 
P = 0.215, VTD; P = 0.240, PAD; P = 0.047, and VMP; P = 0.345). 
Though the differences were not significant, the early respond-
ers tended to have better outcomes than the delayed respond-
ers when stratified by chemotherapeutic regimen. 
 On further analysis, PFS and OS were compared between 
group A and B according to International Staging System (ISS). 
In ISS I and II, The 3 yr PFS were higher in the A group than the 
B group (P < 0.001 and P < 0.001). The 3 yr OS tended to be high-
Table 2. Comparison of the early good (group A) and poor (group B) response groups 
Parameters
Group A  
(VGPR, CR)  
(n = 66)
Group B  
(PR, SD, PD)  
(n = 63)
P  value 
Age, yr, No (%) 
  < 65 
  ≥ 65 
  
37 (56.1)
29 (43.9)
  
38 (60.3)
25 (39.7)
0.624 
Sex, No (%)
   Male 
   Female 
 
35 (53.0)
31 (47.0) 
 
32 (50.8)
31 (49.2)
0.799 
Serum M-protein, No (%) 
   IgG, κ type 
   IgG, λ type 
   IgA, κ type 
   IgA, λ type 
   Free κ type 
   Free λ type 
 
21 (31.8) 
16 (24.2) 
7 (10.6) 
11 (16.7) 
7 (10.6) 
4 (6.1) 
 
29 (46.0) 
15 (23.8) 
7 (11.1) 
3 (4.8) 
3 (4.8) 
6 (9.5) 
0.167 
ISS staging, No (%)  
   I 
   II  
   III 
 
14 (21.2) 
26 (39.4) 
26 (39.4) 
 
15 (23.8) 
26 (41.3) 
22 (34.9) 
0.861 
Cytogenetics, No (%) 
   Unknown  
   Normal 
   Abnormal 
 
25 (37.9) 
15 (22.7) 
26 (39.4) 
 
29 (46.0) 
8 (12.7) 
26 (41.3)
0.308 
CRP, No (%) 
   Unknown 
  ≥ 1.0 
  < 1.0 
 
12 (18.2)
24 (36.4)
30 (45.5)
 
5 (7.9) 
18 (28.6) 
40 (63.5) 
0.078 
Beta-2 microglobulin, mg/L, No (%) 
   Unknown 
  < 2.5 
   2.5-5.5 
  > 5.5 
 
2 (3.0) 
6 (9.1) 
33 (50.0) 
25 (37.9) 
 
0 (0.0) 
10 (15.9) 
32 (50.8) 
21 (33.3) 
0.348 
Albumin, g/L, No (%) 
  < 3.5 
  ≥ 3.5 
 
34 (51.5) 
32 (48.5)
 
32 (50.8) 
31 (49.2) 
0.935 
Calcium, mg/dL, No (%) 
   Unknown 
  ≤ 10 
  > 10 
1 (1.5) 
55 (83.3) 
10 (15.2) 
0 (0.0) 
56 (88.9) 
7 (11.1) 
0.480 
LDH, IU/L, No (%) 
   Unknown 
  < 450 
  ≥ 450 
 
4 (6.1) 
49 (74.2)
13 (19.7) 
 
3 (4.8) 
50 (79.4)
10 (15.9) 
0.789 
Creatinine, mg/dL, No (%) 
  < 1.5 
  ≥ 1.5 
 
45 (68.2) 
21 (31.8)
 
49 (77.8) 
14 (22.2) 
0.220 
Bone lesion, number, No (%) 
   Unknown 
   None 
   1-3 
  > 3 
 
1 (1.5) 
12 (18.2) 
22 (33.3) 
31 (47.0)
 
1 (1.6) 
17 (27.0) 
17 (27.0) 
28 (44.4) 
0.662 
First line regimen, No (%)  
   VD 
   VTD 
   PAD 
   VMP 
 
23 (34.8) 
24 (36.4)
9 (13.6) 
10 (15.2)
 
34 (54.0) 
8 (12.7) 
9 (14.3) 
12 (19.0) 
0.017 
Performed CTx cycles, No (%) 
  ≤ 6 
  > 6 
 
39 (59.1)
27 (40.9) 
 
44 (69.8)
19 (30.2) 
0.203 
Additional CTx after first line CTx, No (%)
   0 
   1
   2
  ≥ 3
 
44 (66.7)
9 (13.6)
7 (10.6)
6 (9.1)
 
23 (36.5)
17 (27.0)
12 (19.0)
11 (17.5)
0.008
ISS, International staging system; LDH, lactate dehydrogenase; CRP, C-reactive pro-
tein; VD, velcade plus dexamethasone; VTD, velcade, thalidomide plus dexametha-
sone; PAD, doxorubicin, velcade plus dexamethasone; VMP, velcade, melphalan plus 
prednisone; CTx, chemotherapy. 
Table 3. Response to chemotherapy
Responses Frequency (%) Cumulative percent (%) 
Early response 
   CR 
   VGPR 
   PR 
   SD 
   PD 
 
  16 (12.4) 
  50 (38.8) 
  40 (31.0) 
  14 (10.9) 
  9 (7.0) 
 
  12.4 
  51.2 
  82.2 
  93.0 
100.0 
Best response 
   CR 
   VGPR 
   PR 
   SD 
   PD 
  46 (35.7) 
  31 (24.0) 
  32 (24.8) 
11 (8.5) 
  9 (7.0) 
  35.7 
  59.7 
  84.5 
  93.0 
100.0 
CR, complete response; VGPR, very good partial response; PR, partial response; SD, 
stable disease; PD, progressive disease. 
Table 4. Survival rates after chemotherapy
Responses 3-yr PFS P  value 3-yr OS P  value 
Early response 
   VGPR, CR (n = 66) 
   PR, SD, PD (n = 63) 
 
55.6 
18.4 
 
< 0.001 
 
65.3 
52.9 
 
0.078 
Response 
   Early response (n = 66) 
   Delayed response (n = 11) 
 
55.6 
33.3 
 
    0.031 
 
65.3 
50.0 
 
0.831 
CR, complete response; VGPR, very good partial response; PR, partial response; SD, 
stable disease; PD, progressive disease; PFS, progression free survival rates; OS, 
overall survival rates, early response, more than PR at least four cycles or less than 
4 months; delayed response, more than PR after four cycles or 4 months. 
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er in the A group than the B group, though the difference was 
not statistically significant (P = 0.718 and P = 0.182). However, 
in ISS III, The 3 yr PFS and OS were higher in the A group than 
the B group (P < 0.001 and P < 0.042).
DISCUSSION
In some studies, achieving a CR (or the maximal response) has 
been associated with the long-term outcome of MM patients 
who were ineligible for stem cell transplantation (11-13, 23, 24). 
The addition of bortezomib, thalidomide, and lenalidomide to 
first-line therapies for nontransplant MM patients has resulted 
in high CR and VGPR rates in some pahse III studies (19, 23, 25). 
The VISTA trial, in which bortezomib plus MP (VMP) was com-
pared with MP alone in terms of CR or VGPR versus PR, dem-
onstrated that VMP was associated significantly with a longer 
time to progression (TTP, P = 0.025), a longer time to next ther-
apy (TTNT, P = 0.005) and a longer treatment-free interval (TFI, 
P = 0.002), but not with longer OS (P = 0.54). 
 There have been some reports that the early response is pre-
dictive of the therapeutic coutcome. Schaar and colleagues (17) 
studied the relationship between survival and the rate of M pro-
tein decrease during the first cycles of therapy in newly-diag-
nosed MM patients. The survival advantage was seen for pati- 
ents who had an M protein decrease of at least 30%, indicating 
that an early response to MP predicted survival in MM. Ross et 
al. (15) demonstrated that patients with a ≥ 50% reduction in 
monoclonal protein after the first cycles of VAD had a signifi-
cantly better EFS than patients with < 50% reduction (P = 0.002). 
A recent report by Shah and colleagues (21) focused on patients 
with relapsed or refractory MM treated with a novel agent. The 
study showed that patients with a 50% or greater, and especially 
those with a 75% or greater, reduction in M protein levels at cy-
cle 2 had a significant decreased risk for TTP, compared with pa-
Fig. 1. Comparison of progression free survival (PFS) and overall survival (OS) rates between the early good and poor response groups. The early good response group has a 
higher PFS (P < 0.001) (A). The early good response group tends to have a higher OS (P = 0.0078) (B). CR, complete response; VGPR, very good partial response; PR, partial 
response; SD, stable disease; PD, progressive disease.
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Fig. 2. Comparison of progression free survival (PFS) and overall survival (OS) rates between the early and delayed response groups. The early response group has a higher 
PFS (P = 0.031) (A). There is shown no difference between the groups in terms of OS (P = 0.831) (B). CR, complete response; VGPR, very good partial response; PR, partial re-
sponse; SD, stable disease; PD, progressive disease.
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tients with less than a 25% reduction. Thus early decreases in M 
protein may provide better outcomes in patients treated with 
bortezomib combined chemotherapy. Palumbo (16) also report-
ed the possibility of using a response marker in the early phases 
of therapy to predict outcome, but until now there have been 
no data about the early response in MM patients who were not 
eligible for HSCT treated with novel agents as first-line therapy.
 In our study, all patients, who were treated with bortezomib 
combined chemotherapy, were divided into a good response 
group, which included patients with a VGPR or better, and a 
poor response group, which included patients with a PR or worse. 
The groups were determined based on patient responses before 
cycle 4 or 4 months after starting chemotherapy. The 3 yr PFS of 
the good response group was higher than the poor response 
group (P < 0.001), though the 3 yr OS did not differ (P = 0.078). 
No significant differences of OS between two groups might be 
influenced by more numbers of chemotherapy after first line 
chemotherapy in group B than those in group A in based of pa-
tients characteristics. Moreover, within the good response group, 
patients with an early response had significantly higher survival 
rates than patients with a delayed response. The 3 yr PFS was 
higher in the early response group than the delayed response 
group (P = 0.031), but the 3 yr OS did not differ (P = 0.831). 
 This study has several limitations. We used retrospective med-
ical record review at the nationwide registry of MM patients. 
More research is needed to investigate the effect of early respons-
es to novel agents on MM outcomes.
 In summary, our results suggest that patients that have a ear-
ly good response to bortezomib combined chemotherapy as 
first-line therapy have longer PFS than those that have a poor 
response by cycle 4 or 4 months after starting chemotherapy. 
An early response may be predictive for survival outcomes in 
nontransplant candidate patients with MM treated with bort-
ezomib combined chemotherapy. 
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